207 related articles for article (PubMed ID: 33323872)
1. Primary Biliary Cirrhosis and Granulomatous Hepatitis After Immune Checkpoint Blockade in Patients With Metastatic Melanoma: Report of 2 Cases and Literature Discussion.
Ruini C; Haas C; Mastnik S; Knott M; French LE; Schlaak M; Berking C
J Immunother; 2021 Feb-Mar 01; 44(2):71-75. PubMed ID: 33323872
[TBL] [Abstract][Full Text] [Related]
2. Encephalitis in a Patient With Melanoma Treated With Immune Checkpoint Inhibitors: Case Presentation and Review of the Literature.
Gkoufa A; Gogas H; Diamantopoulos PT; Ziogas DC; Psichogiou M
J Immunother; 2020 Sep; 43(7):224-229. PubMed ID: 32554976
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 expressing granulomatous reaction as an on-target mechanism of steroid-refractory immune hepatotoxicity.
Black JR; Goldin RD; Foxton M; Marafioti T; Akarca AU; Pria AD; Brock C; Bower M; Pinato DJ
Immunotherapy; 2019 May; 11(7):585-590. PubMed ID: 30943859
[TBL] [Abstract][Full Text] [Related]
4. Encephalitis Associated With Immune Checkpoint Inhibitor Treatment in Patients With Melanoma.
Martínez-Vila C; Laguna JC; Segui E; Ruiz G; Aya Moreno F; Fernandez-Morales LM; Giner Joaquim J; Padrosa J; Fernandez L; Gaba L; Victoria I; Arance Fernandez AM
J Immunother; 2021 Jun; 44(5):204-207. PubMed ID: 33950029
[TBL] [Abstract][Full Text] [Related]
5. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
[TBL] [Abstract][Full Text] [Related]
6. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.
Li M; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
Cancer; 2020 Dec; 126(23):5088-5097. PubMed ID: 32888341
[TBL] [Abstract][Full Text] [Related]
7. Granulomatous hepatitis. A review of 50 cases.
Mir-Madjlessi SH; Farmer RG; Hawk WA
Am J Gastroenterol; 1973 Aug; 60(2):122-34. PubMed ID: 4741106
[No Abstract] [Full Text] [Related]
8. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
[TBL] [Abstract][Full Text] [Related]
9. Management of immune-related hepatitis in patients being treated with checkpoint inhibitors for metastatic melanoma, a review and case series.
Tew A; Khoja L; Pallan L; Steven N
J Oncol Pharm Pract; 2023 Jul; 29(5):1163-1171. PubMed ID: 35607278
[TBL] [Abstract][Full Text] [Related]
10. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
Dougan M; Blidner AG; Choi J; Cooksley T; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Anderson R; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6129-6143. PubMed ID: 32856210
[TBL] [Abstract][Full Text] [Related]
11. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
Brown LJ; Weppler A; Bhave P; Allayous C; Patrinely JR; Ott P; Sandhu S; Haydon A; Lebbe C; Johnson DB; Long GV; Menzies AA; Carlino MS
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963010
[TBL] [Abstract][Full Text] [Related]
12. Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update.
Kähler KC; Hassel JC; Heinzerling L; Loquai C; Thoms KM; Ugurel S; Zimmer L; Gutzmer R;
J Dtsch Dermatol Ges; 2020 Jun; 18(6):582-609. PubMed ID: 32489011
[TBL] [Abstract][Full Text] [Related]
13. Combination Therapy of Ipilimumab and Nivolumab-associated Toxic Epidermal Necrolysis (TEN) in a Patient With Metastatic Melanoma: A Case Report and Literature Review.
Logan IT; Zaman S; Hussein L; Perrett CM
J Immunother; 2020 Apr; 43(3):89-92. PubMed ID: 31651559
[TBL] [Abstract][Full Text] [Related]
14. Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience.
Vitale G; Lamberti G; Comito F; Di Nunno V; Massari F; Morelli MC; Ardizzoni A; Gelsomino F
Expert Opin Biol Ther; 2020 Sep; 20(9):1047-1059. PubMed ID: 32425081
[TBL] [Abstract][Full Text] [Related]
15. Sudden Otovestibular Dysfunction in 3 Metastatic Melanoma Patients Treated With Immune Checkpoint Inhibitors.
Stürmer SH; Lechner A; Berking C
J Immunother; 2021 Jun; 44(5):193-197. PubMed ID: 33734141
[TBL] [Abstract][Full Text] [Related]
16. Facial palsy after administration of immune checkpoint inhibitors: case report, literature review and clinical care management.
Mezni E; Corazza G; Mari R; Coze S; Charrier N; Chanez B; Chretien AS; Rochigneux P
Front Immunol; 2024; 15():1375497. PubMed ID: 38585263
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitors in melanoma.
Carlino MS; Larkin J; Long GV
Lancet; 2021 Sep; 398(10304):1002-1014. PubMed ID: 34509219
[TBL] [Abstract][Full Text] [Related]
18. Safe administration of anti-PD-1 immunotherapy in a patient with pre-existing primary biliary cholangitis.
Bhave P; Pham A; Gordon A; Moore M
Immunotherapy; 2020 May; 12(7):445-450. PubMed ID: 32308090
[TBL] [Abstract][Full Text] [Related]
19. Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis.
Tarhini AA; Kang N; Lee SJ; Hodi FS; Cohen GI; Hamid O; Hutchins LF; Sosman JA; Kluger HM; Eroglu Z; Koon HB; Lawrence DP; Kendra KL; Minor DR; Lee CB; Albertini MR; Flaherty LE; Petrella TM; Streicher H; Sondak VK; Kirkwood JM
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963015
[TBL] [Abstract][Full Text] [Related]
20. Autoimmune Colitis and Subsequent CMV-induced Hepatitis After Treatment With Ipilimumab.
Uslu U; Agaimy A; Hundorfean G; Harrer T; Schuler G; Heinzerling L
J Immunother; 2015 Jun; 38(5):212-5. PubMed ID: 25962110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
